Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug tolerance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    415 result(s) found for: Drug tolerance. Displaying page 1 of 21.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-004250-81 Sponsor Protocol Number: AKREMITOLFMRI1 Start Date*: 2007-09-11
    Sponsor Name:Helsinki University Central Hospital, Pain Clinic
    Full Title: Acute opioid tolerance as revealed by functional magnetic resonance imaging.
    Medical condition: akuutti opioiditoleranssi
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052804 Drug tolerance LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-002084-49 Sponsor Protocol Number: 06023GM-A Start Date*: 2006-09-13
    Sponsor Name:Belfast City Hospital Trust
    Full Title: Vascular function in impaired glucose tolerance - effect of pioglitazone
    Medical condition: Impaired glucose tolerance
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002249-13 Sponsor Protocol Number: TN-18 Start Date*: 2014-09-11
    Sponsor Name:TrialNet Coordinating Center
    Full Title: CTLA-4Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
    Medical condition: A soluble fusion protein, CTLA-4 Ig, is to be used for the prevention of abnormal glucose tolerance and diabetes in relatives at risk of developing the disease.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10042613 - Surgical and medical procedures 10066284 Diabetes prophylaxis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) DE (Completed) FI (Completed) IT (Ongoing) SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002027-16 Sponsor Protocol Number: RPCG06B2433 Start Date*: 2006-12-12
    Sponsor Name:UCB AE
    Full Title: Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subseq...
    Medical condition: Certolizumab pegol in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005744-24 Sponsor Protocol Number: DM-99-07 Start Date*: 2008-02-11
    Sponsor Name:DiaMedica Inc.
    Full Title: A phase IIa, placebo controlled, randomized, cross-over study to evaluate the effects of DM-99 on a meal tolerance test in subjects with type 2 diabetes mellitus
    Medical condition: Cukrzyca
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002225-26 Sponsor Protocol Number: 280789 Start Date*: 2019-10-22
    Sponsor Name:HOSPITAL UNIVERSITARIO FUNDACION ALCORCON
    Full Title: EVALUATION OF THE COFACTORS IN THE MAINTENANCE PHASE REACTIONS AFTER MILK AND EGG ORAL IMMUNOTHERAPY
    Medical condition: Investigate the role of the drug in the possible allergic reactions as a cofactor
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004571-73 Sponsor Protocol Number: SOCOGAMI Start Date*: 2017-12-15
    Sponsor Name:Karolinska Institutet, Stockholm, Sweden [...]
    1. Karolinska Institutet, Stockholm, Sweden
    2. Karolinska Institutet
    3. Karolinska Institutet
    Full Title: SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities post Myocardial Infarction (SOCOGAMI)
    Medical condition: Patients with acute coronary syndromes (myocardial infarction or unstable angina pectoris) with newly detected glucose perturbations (impaired glucose tolerance or type 2 diabetes)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000121-31 Sponsor Protocol Number: PSYK-TREAT-HEALTHY Start Date*: 2013-03-20
    Sponsor Name:Prof., dr. med. Anders Fink-Jensen
    Full Title: Does a GLP-1 receptor agonist change glucose tolerance in antipsychotic-treated patients?
    Medical condition: Dysglycaemia, schizophrenia, paranoid psycosis, schizotypal disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10036481 Pre-diabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003477-18 Sponsor Protocol Number: Empabrain01 Start Date*: 2017-05-04
    Sponsor Name:University Hospital Tuebingen
    Full Title: A double-blind randomized study to determine the effect of empagliflozin versus placebo on brain insulin sensitivity in patients with prediabetes
    Medical condition: brain insulin sensitivity in patients with prediabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003170-44 Sponsor Protocol Number: VX19-445-117 Start Date*: 2020-11-30
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3b Open-label Study to Assess the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) FR (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018708-99 Sponsor Protocol Number: 1245.39 Start Date*: 2010-10-19
    Sponsor Name:BOEHRINGER ING.
    Full Title: An open-label, phase IIb study to determine acute (after the first dose administration) and chronic (after 28 days of treatment) effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor ...
    Medical condition: patients with IGT or type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 LLT
    9.1 10018429 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015768-33 Sponsor Protocol Number: EMR700773-003/BMN162-503 Start Date*: 2011-01-04
    Sponsor Name:BioMarin International Ltd.
    Full Title: A Phase IIIb, Multicentre, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan®) in Phenylketonuria (PKU) Patient...
    Medical condition: Phenylketonuria
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10034873 Phenylketonuria (PKU) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) DE (Completed) AT (Completed) CZ (Completed) PT (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003821-40 Sponsor Protocol Number: NN7170-4345 Start Date*: 2017-02-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed) AT (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000975-18 Sponsor Protocol Number: M13-397 Start Date*: 2012-09-26
    Sponsor Name:Abbott Laboratories GmbH
    Full Title: Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects with Nonalcoholic Steatohepatitis (NASH) and no...
    Medical condition: Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006878-22 Sponsor Protocol Number: R00002 CR 201 (ORF) Start Date*: 2007-12-11
    Sponsor Name:Orfagen
    Full Title: Efficacy and tolerance of Tazarotene cream in lamellar ichthyosis (LI): a dose-finding study.
    Medical condition: Lamellar Ichthyosis (LI)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003207-35 Sponsor Protocol Number: APCP-115,amendment Start Date*: 2013-08-13
    Sponsor Name:Karolinska University Hospital Solna
    Full Title: Effects of ARA 290, a non-hematopoietic erythropoietin analog, on glucose tolerance, insulin secretion, insulin sensitivity and long-term glucose control in individuals with prediabetes and/or dru...
    Medical condition: For the complementary visits; up to 12 Subjects with Prediabetes (impaired fasting glucose, impaired glucose tolerance) or diet-treated type 2 diabetes, will be chosen from the currently approved c...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10065542 Prediabetes LLT
    17.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002517-18 Sponsor Protocol Number: PROICM2020-04GAB Start Date*: 2020-10-19
    Sponsor Name:Institut régional du cancer de Montpellier (ICM)
    Full Title: Phase II study evaluating the benefit of sequential treatment with Gemcitabine/Nab-Paclitaxel (Gembrax) then Folfirinox followed by adaptative MRI-guided stereotactic radiotherapy in patients with ...
    Medical condition: Locally advanced adenocarcinoma of pancreas
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033600 Pancreatic adenocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004329-90 Sponsor Protocol Number: OGTT Version 3. 18.05.07 Start Date*: 2005-02-08
    Sponsor Name:CAMBRIDGE UNIVERSITY HOSPITALS FOUNDATION NHS TRUST
    Full Title: EARLY METABOLIC CHANGES WITH THIAZIDE OR BETA BLOCKER THERAPY FOR ESSENTIAL HYPERTENSION (MAIN STUDY).
    Medical condition: ESSENTIAL HYPERTENSION
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004946-41 Sponsor Protocol Number: s57223 Start Date*: 2014-11-19
    Sponsor Name:KULeuven
    Full Title: The influence of GLP-1 analog, liraglutide, on gastric accommodation, gastric emptying, hunger and the migrating motor complex in healthy volunteers
    Medical condition: healthy volunteers no medical condition; drug will be studied because it is known to influence gastric motility
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003381-27 Sponsor Protocol Number: 100045 Start Date*: 2018-09-24
    Sponsor Name:CEA
    Full Title: Study in 18F-DPA714 PET to better locate preoperatively the epileptic focus to resect in drug-resistant partial epilepsy
    Medical condition: Brain imaging on people with partial pharmaco resistant epilepsy
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 13 19:09:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA